SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Tricot, G Articles by Barlogie, B Search for Related Content PubMed PubMed Citation Articles by Tricot, G Articles by Barlogie, B Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Graft-versus-myeloma effect: proof of principle G Tricot, DH Vesole, S Jagannath, J Hilton, N Munshi and B Barlogie Division of Hematology/Oncology, University of Arkansas for Medical Sciences, Little Rock, USA. The presence of a graft-versus-tumor effect has been well established in leukemia but not in multiple myeloma. A 40-year-old patient with myeloma refractory to standard chemotherapy and autologous transplantation received a matched unrelated T-cell-depleted transplant after conditioning with fractionated total-body irradiation, thiotepa, and cyclophosphamide. This procedure resulted in a transient and incomplete response with evidence of rapidly progressive disease within 2.5 months posttransplantation. The patient then received a small number of donor peripheral blood (PB) mononuclear cells (CD3 cells 1.2 x 10(6)/kg) without any further cytotoxic therapy. A complete remission was attained, lasting now for more than 14 months. The procedure was associated with severe acute and subsequently limited chronic graft- versus-host disease (GVHD). This report provides the first direct evidence of a graft-versus-myeloma effect after allogenic transplantation. Volume 87, Issue 3, pp. 1196-1198, 02/01/1996 Copyright © 1996 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: C. Fionda, A. Soriani, G. Malgarini, M. L. Iannitto, A. Santoni, and M. Cippitelli Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation J. Immunol., October 1, 2009; 183(7): 4385 - 4394. [Abstract] [Full Text] [PDF] A. P. Rapoport, E. A. Stadtmauer, N. Aqui, D. Vogl, A. Chew, H.-B. Fang, S. Janofsky, K. Yager, E. Veloso, Z. Zheng, et al. Rapid Immune Recovery and Graft-versus-Host Disease-like Engraftment Syndrome following Adoptive Transfer of Costimulated Autologous T Cells Clin. Cancer Res., July 1, 2009; 15(13): 4499 - 4507. [Abstract] [Full Text] [PDF] M. Rotta, B. E. Storer, F. Sahebi, J. A. Shizuru, B. Bruno, T. Lange, E. D. Agura, P. A. McSweeney, M. A. Pulsipher, P. Hari, et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting Blood, April 2, 2009; 113(14): 3383 - 3391. [Abstract] [Full Text] [PDF] B. Bruno, M. Rotta, F. Patriarca, D. Mattei, B. Allione, F. Carnevale-Schianca, R. Sorasio, A. Rambaldi, M. Casini, M. Parma, et al. Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo Blood, April 2, 2009; 113(14): 3375 - 3382. [Abstract] [Full Text] [PDF] D. Atanackovic, T. Luetkens, Y. Hildebrandt, J. Arfsten, K. Bartels, C. Horn, T. Stahl, Y. Cao, A. R. Zander, C. Bokemeyer, et al. Longitudinal Analysis and Prognostic Effect of Cancer-Testis Antigen Expression in Multiple Myeloma Clin. Cancer Res., February 15, 2009; 15(4): 1343 - 1352. [Abstract] [Full Text] [PDF] H.-J. Kolb Graft-versus-leukemia effects of transplantation and donor lymphocytes Blood, December 1, 2008; 112(12): 4371 - 4383. [Abstract] [Full Text] [PDF] W. Song, H. J.J. van der Vliet, Y.-T. Tai, R. Prabhala, R. Wang, K. Podar, L. Catley, M. A. Shammas, K. C. Anderson, S. P. Balk, et al. Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy Clin. Cancer Res., November 1, 2008; 14(21): 6955 - 6962. [Abstract] [Full Text] [PDF] J. Qian, J. Xie, S. Hong, J. Yang, L. Zhang, X. Han, M. Wang, F. Zhan, J. D. Shaughnessy Jr, J. Epstein, et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma Blood, September 1, 2007; 110(5): 1587 - 1594. [Abstract] [Full Text] [PDF] B. Bruno, M. Rotta, F. Patriarca, N. Mordini, B. Allione, F. Carnevale-Schianca, L. Giaccone, R. Sorasio, P. Omede, I. Baldi, et al. A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma N. Engl. J. Med., March 15, 2007; 356(11): 1110 - 1120. [Abstract] [Full Text] [PDF] M. Condomines, D. Hose, P. Raynaud, M. Hundemer, J. De Vos, M. Baudard, T. Moehler, V. Pantesco, M. Moos, J.-F. Schved, et al. Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis J. Immunol., March 1, 2007; 178(5): 3307 - 3315. [Abstract] [Full Text] [PDF] H. Lokhorst No RIC in high-risk myeloma? Blood, May 1, 2006; 107(9): 3420 - 3421. [Full Text] [PDF] F. Garban, M. Attal, M. Michallet, C. Hulin, J. H. Bourhis, I. Yakoub-Agha, T. Lamy, G. Marit, F. Maloisel, C. Berthou, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma Blood, May 1, 2006; 107(9): 3474 - 3480. [Abstract] [Full Text] [PDF] M. Haubitz and D. Peest Myeloma - new approaches to combined nephrological-haematological management Nephrol. Dial. Transplant., March 1, 2006; 21(3): 582 - 590. [Full Text] [PDF] A. Geffroy-Luseau, A. Moreau-Aubry, R. Bataille, and C. Pellat-Deceunynck Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells Int. Immunol., September 1, 2005; 17(9): 1193 - 1200. [Abstract] [Full Text] [PDF] C. Lotz, S. A. Mutallib, N. Oehlrich, U. Liewer, E. A. Ferreira, M. Moos, M. Hundemer, S. Schneider, S. Strand, C. Huber, et al. Targeting Positive Regulatory Domain I-Binding Factor 1 and X Box-Binding Protein 1 Transcription Factors by Multiple Myeloma-Reactive CTL J. Immunol., July 15, 2005; 175(2): 1301 - 1309. [Abstract] [Full Text] [PDF] M. B. Atkins, D. E. Avigan, R. M. Bukowski, R. W. Childs, J. P. Dutcher, T. G. Eisen, R. A. Figlin, J. H. Finke, R. C. Flanigan, D. J. George, et al. Innovations and Challenges in Renal Cancer: Consensus Statement from the First International Conference Clin. Cancer Res., September 15, 2004; 10(18): 6277S - 6281S. [Full Text] [PDF] Y. Takahashi and R. W. Childs Nonmyeloablative Transplantation: An Allogeneic-Based Immunotherapy for Renal Cell Carcinoma Clin. Cancer Res., September 15, 2004; 10(18): 6353S - 6359S. [Abstract] [Full Text] [PDF] C. C. Matte, J. Cormier, B. E. Anderson, I. Athanasiadis, J. Liu, S. G. Emerson, W. Pear, and W. D. Shlomchik Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing Blood, June 1, 2004; 103(11): 4353 - 4361. [Abstract] [Full Text] [PDF] H. M. Lokhorst, K. Wu, L. F. Verdonck, L. L. Laterveer, N. W. C. J. van de Donk, M. H. J. van Oers, J. J. Cornelissen, and A. V. Schattenberg The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma Blood, June 1, 2004; 103(11): 4362 - 4364. [Abstract] [Full Text] [PDF] H.-J. Kolb, C. Schmid, A. J. Barrett, and D. J. Schendel Graft-versus-leukemia reactions in allogeneic chimeras Blood, February 1, 2004; 103(3): 767 - 776. [Abstract] [Full Text] [PDF] B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley Treatment of multiple myeloma Blood, January 1, 2004; 103(1): 20 - 32. [Abstract] [Full Text] [PDF] J. Blade, D. H. Vesole, and M. Gertz Transplantation for multiple myeloma: who, when, how often? Blood, November 15, 2003; 102(10): 3469 - 3477. [Full Text] [PDF] N. T. Ueno, Y. C. Cheng, G. Rondon, N. M. Tannir, J. L. Gajewski, D. R. Couriel, C. Hosing, M. J. de Lima, P. Anderlini, I. F. Khouri, et al. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors Blood, November 15, 2003; 102(10): 3829 - 3836. [Abstract] [Full Text] [PDF] M. Chiriva-Internati, Y. Liu, J. A. Weidanz, F. Grizzi, H. You, W. Zhou, K. Bumm, B. Barlogie, J. L. Mehta, and P. L. Hermonat Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24 Blood, November 1, 2003; 102(9): 3100 - 3107. [Abstract] [Full Text] [PDF] D. G. Maloney, A. J. Molina, F. Sahebi, K. E. Stockerl-Goldstein, B. M. Sandmaier, W. Bensinger, B. Storer, U. Hegenbart, G. Somlo, T. Chauncey, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma Blood, November 1, 2003; 102(9): 3447 - 3454. [Abstract] [Full Text] [PDF] H. M. Lokhorst, C. M. Segeren, L. F. Verdonck, B. van der Holt, R. Raymakers, M. H.J. van Oers, R. M.Y. Barge, H. C. Schouten, P. H.M. Westveer, M. M.C. Steijaert, et al. Partially T-Cell-Depleted Allogeneic Stem-Cell Transplantation for First-Line Treatment of Multiple Myeloma: A Prospective Evaluation of Patients Treated in the Phase III Study HOVON 24 MM J. Clin. Oncol., May 1, 2003; 21(9): 1728 - 1733. [Abstract] [Full Text] [PDF] R. Or, M. Y. Shapira, I. Resnick, A. Amar, A. Ackerstein, S. Samuel, M. Aker, E. Naparstek, A. Nagler, and S. Slavin Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase Blood, January 15, 2003; 101(2): 441 - 445. [Abstract] [Full Text] [PDF] N. Kroger, H. G. Sayer, R. Schwerdtfeger, M. Kiehl, A. Nagler, H. Renges, T. Zabelina, B. Fehse, F. Ayuk, G. Wittkowsky, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality Blood, December 1, 2002; 100(12): 3919 - 3924. [Abstract] [Full Text] [PDF] J. A. Perez-Simon, P. D. Kottaridis, R. Martino, C. Craddock, D. Caballero, R. Chopra, J. Garcia-Conde, D. W. Milligan, S. Schey, A. Urbano-Ispizua, et al. Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders Blood, October 16, 2002; 100(9): 3121 - 3127. [Abstract] [Full Text] [PDF] K. Branson, R. Chopra, P. D. Kottaridis, G. McQuaker, A. Parker, S. Schey, R. K. Chakraverty, C. Craddock, D. W. Milligan, R. Pettengell, et al. Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies J. Clin. Oncol., October 1, 2002; 20(19): 4022 - 4031. [Abstract] [Full Text] [PDF] N. Kroger, R. Schwerdtfeger, M. Kiehl, H. G. Sayer, H. Renges, T. Zabelina, B. Fehse, F. Togel, G. Wittkowsky, R. Kuse, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma Blood, July 18, 2002; 100(3): 755 - 760. [Abstract] [Full Text] [PDF] R. Bellucci, E. P. Alyea, E. Weller, A. Chillemi, E. Hochberg, C. J. Wu, C. Canning, R. Schlossman, R. J. Soiffer, K. C. Anderson, et al. Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma Blood, May 29, 2002; 99(12): 4610 - 4617. [Abstract] [Full Text] [PDF] K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman Multiple Myeloma Hematology, January 1, 2002; 2002(1): 214 - 240. [Abstract] [Full Text] F. Weissinger, B. M. Sandmaier, D. G. Maloney, W. I. Bensinger, T. Gooley, and R. Storb Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings Blood, December 15, 2001; 98(13): 3584 - 3588. [Abstract] [Full Text] [PDF] A. A. Zaidi and D. H. Vesole Multiple Myeloma: An Old Disease with New Hope for the Future CA Cancer J Clin, September 1, 2001; 51(5): 273 - 285. [Abstract] [Full Text] [PDF] E. Alyea, E. Weller, R. Schlossman, C. Canning, I. Webb, D. Doss, P. Mauch, K. Marcus, D. Fisher, A. Freeman, et al. T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect Blood, August 15, 2001; 98(4): 934 - 939. [Abstract] [Full Text] [PDF] M. Michallet, K. Bilger, F. Garban, M. Attal, A. Huyn, D. Blaise, N. Milpied, P. Moreau, P. Bordigoni, M. Kuentz, et al. Allogeneic Hematopoietic Stem-Cell Transplantation After Nonmyeloablative Preparative Regimens: Impact of Pretransplantation and Posttransplantation Factors on Outcome J. Clin. Oncol., July 15, 2001; 19(14): 3340 - 3349. [Abstract] [Full Text] [PDF] R. A. Kyle Update on the Treatment of Multiple Myeloma Oncologist, April 1, 2001; 6(2): 119 - 124. [Abstract] [Full Text] N. C. Munshi Arsenic Trioxide: An Emerging Therapy for Multiple Myeloma Oncologist, April 1, 2001; 6(90002): 17 - 21. [Abstract] [Full Text] W. S. Dalton, P. L. Bergsagel, W. M. Kuehl, K. C. Anderson, and J. L. Harousseau Multiple Myeloma Hematology, January 1, 2001; 2001(1): 157 - 177. [Abstract] [Full Text] [PDF] H. M. Lokhorst, A. Schattenberg, J. J. Cornelissen, M. H. J. van Oers, W. Fibbe, I. Russell, N. W. C. J. v. d. Donk, and L. F. Verdonck Donor Lymphocyte Infusions for Relapsed Multiple Myeloma After Allogeneic Stem-Cell Transplantation: Predictive Factors for Response and Long-Term Outcome J. Clin. Oncol., August 16, 2000; 18(16): 3031 - 3037. [Abstract] [Full Text] [PDF] M. H. Hsieh and R. Korngold Differential use of FasL- and perforin-mediated cytolytic mechanisms by T-cell subsets involved in graft-versus-myeloid leukemia responses Blood, August 1, 2000; 96(3): 1047 - 1055. [Abstract] [Full Text] [PDF] M. Mielcarek, W. Leisenring, B. Torok-Storb, and R. Storb Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect Blood, August 1, 2000; 96(3): 1150 - 1156. [Abstract] [Full Text] [PDF] R. Desikan, B. Barlogie, J. Sawyer, D. Ayers, G. Tricot, A. Badros, M. Zangari, N. C. Munshi, E. Anaissie, D. Spoon, et al. Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities Blood, June 15, 2000; 95(12): 4008 - 4010. [Abstract] [Full Text] [PDF] N. van Baren, F. Brasseur, D. Godelaine, G. Hames, A. Ferrant, F. Lehmann, M. Andre, C. Ravoet, C. Doyen, G. C. Spagnoli, et al. Genes Encoding Tumor-Specific Antigens Are Expressed in Human Myeloma Cells Blood, August 15, 1999; 94(4): 1156 - 1164. [Abstract] [Full Text] [PDF] M. Massaia, P. Borrione, S. Battaglio, S. Mariani, E. Beggiato, P. Napoli, C. Voena, A. Bianchi, M. Coscia, B. Besostri, et al. Idiotype Vaccination in Human Myeloma: Generation of Tumor-Specific Immune Responses After High-Dose Chemotherapy Blood, July 15, 1999; 94(2): 673 - 683. [Abstract] [Full Text] [PDF] P. Corradini, C. Voena, C. Tarella, M. Astolfi, M. Ladetto, A. Palumbo, M. T. Van Lint, A. Bacigalupo, A. Santoro, M. Musso, et al. Molecular and Clinical Remissions in Multiple Myeloma: Role of Autologous and Allogeneic Transplantation of Hematopoietic Cells J. Clin. Oncol., January 1, 1999; 17(1): 208 - 208. [Abstract] [Full Text] [PDF] H.M. Lokhorst, A. Schattenberg, J.J. Cornelissen, L.L.M. Thomas, and L.F. Verdonck Donor Leukocyte Infusions Are Effective in Relapsed Multiple Myeloma After Allogeneic Bone Marrow Transplantation Blood, November 15, 1997; 90(10): 4206 - 4211. [Abstract] [Full Text] [PDF] R. Bataille and J.-L. Harousseau Multiple Myeloma N. Engl. J. Med., June 5, 1997; 336(23): 1657 - 1664. [Full Text] [PDF] T. H. Landowski, M. C. Gleason-Guzman, and W. S. Dalton Selection for Drug Resistance Results in Resistance to Fas-Mediated Apoptosis Blood, March 15, 1997; 89(6): 1854 - 1861. [Abstract] [Full Text] [PDF] N.C. Munshi, R. Govindarajan, R. Drake, L.M. Ding, R. Iyer, R. Saylors, J. Kornbluth, S. Marcus, Y. Chiang, D. Ennist, et al. Thymidine Kinase (TK) Gene-Transduced Human Lymphocytes Can Be Highly Purified, Remain Fully Functional, and Are Killed Efficiently With Ganciclovir Blood, February 15, 1997; 89(4): 1334 - 1340. [Abstract] [Full Text] [PDF] B. Barlogie, S. Jagannath, D. H. Vesole, S. Naucke, B. Cheson, S. Mattox, D. Bracy, S. Salmon, J. Jacobson, J. Crowley, et al. Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma Blood, February 1, 1997; 89(3): 789 - 793. [Abstract] [Full Text] [PDF] Z. S. Pavletic and J. O. Armitage Bone Marrow Transplantation for Cancer--An Update Oncologist, June 1, 1996; 1(3): 159 - 168. [Abstract] [Full Text] [PDF]

	Copyright © 1996 by American Society of Hematology         Online ISSN: 1528-0020